Related by context. All words. (Click for frequent words.) 68 BRIM3 68 phase IIa 67 oral ridaforolimus 67 MAGE A3 ASCI 67 tolevamer 67 multicenter Phase II 67 Phase #b/#a 67 CHAMPION PCI 67 Phase IIb clinical trials 67 confirmatory clinical 66 midstage trials 66 phase IIIb 66 GLP toxicology studies 66 Phase 1a clinical 66 PRIMO CABG 66 Phase Ib clinical 66 TBC# 66 Phase IIb III 66 phase IIb trial 66 Phase Ib study 66 CRMD# 66 phase IIb clinical 65 phase Ib 65 Phase Ib II 65 phase IIb study 65 clinical pharmacology studies 65 APEX AMI 65 Phase IIB 65 preclinical pharmacokinetic 65 Cloretazine 65 Phase IIIb clinical 65 tramiprosate Alzhemed TM 65 thorough QT 65 midstage clinical 65 pivotal bioequivalence 65 rALLy trial 65 Proellex TM 64 randomized Phase IIb 64 NP2 Enkephalin 64 riociguat 64 GLP1 agonist 64 EmbraceAC 64 Atrasentan 64 ADVANCE PD 64 Phase IIIb study 64 alvespimycin 64 UVIDEM 64 clevidipine 64 Amoxicillin PULSYS Phase III 64 forodesine 64 dexanabinol 64 ZOLINZA 64 oral methylnaltrexone 64 APEX AMI trial 64 ICA # 64 AMPAKINE CX# 64 EMPHASIS HF trial 64 identifier NCT# 64 Triapine R 64 INCB# [001] 64 budesonide foam 64 Phase III randomized controlled 63 trastuzumab DM1 T DM1 63 Zemplar Capsules 63 Specifid 63 VNP#M 63 Androxal TM 63 PSMA ADC 63 phase IIa clinical 63 IMPACT DCM 63 UPLYSO 63 mertansine 63 Tarceva TM 63 PRECISE Trial 63 AZILECT ® 63 unblinding 63 RSD# oral 63 pharmacokinetic PK study 63 ONCONASE R 63 fosbretabulin 63 BRIM2 63 DSMB recommended 63 treatment naive genotype 63 STRIDE PD 63 RhuDex 63 IIa trial 63 Trofex 63 solithromycin 63 IMPACT DCM clinical 63 Corlux 63 TLK# 63 dose escalation phase 63 BrachySil TM 63 dose escalation Phase 63 Phase 2b study 63 GRAVITAS trial 63 YONDELIS 63 SUCCEED trial 63 Ocrelizumab 63 LAB CGRP 62 GRNVAC1 62 radiolabeled TM# 62 Aplidin 62 SPARLON 62 Dose escalation 62 galiximab 62 Enzastaurin 62 Phase 1b trial 62 phase III isavuconazole 62 randomized discontinuation trial 62 incyclinide 62 dose titration 62 reslizumab 62 BETAS 62 Dacogen injection 62 Zenvia Phase III 62 TASKi3 62 Hepatocellular Carcinoma HCC 62 Dacogen decitabine 62 GENASIS 62 non nucleoside HCV 62 HuMax EGFr 62 OvaRex ® MAb 62 PRIMO CABG2 62 bevirimat Study 62 acyclovir Lauriad R 62 Phase IIa trial 62 Glypromate 62 Teysuno 62 OvaRex R 62 vismodegib 62 postapproval 62 PrevOnco 62 subcutaneous PRO 62 brivaracetam 62 Phase 2a clinical trials 62 oxymorphone ER 62 MyVax 62 MERLIN TIMI 62 Raptiva efalizumab 62 teriflunomide 62 TYGACIL 62 elotuzumab 62 phase IIb 62 ACTIVE W 62 eculizumab therapy 62 nonclinical studies 62 TELINTRA 62 dosing cohort 62 dose cohort 62 Cloretazine ® 62 Ataluren 62 GSK# [001] 62 Genz # 62 oral deforolimus 62 HCV RESPOND 2 62 bioequivalency 62 MYCAMINE 62 AIM HIGH 62 MEND CABG 62 Cimzia TM 62 phase IIb III 62 iii GTx 62 Phase IIa trials 62 Raptiva ® 62 TRA 2P 62 faropenem 62 multidose 62 VITAL Trial 62 Hedgehog antagonist 62 isatoribine 62 Azedra 62 TELCYTA 61 bovine thrombin 61 Alzhemed TM 61 sitaxsentan 61 ELACYT 61 EOquin TM 61 GLPG# 61 clinical trial 61 huN# DM1 61 multicenter Phase 61 ruxolitinib 61 Oglemilast 61 anagrelide 61 MyVax personalized immunotherapy 61 Anturol TM 61 MGd 61 Certolizumab pegol 61 Plenaxis TM 61 thalidomide Thalomid 61 enzastaurin 61 Fodosine 61 preclinical efficacy 61 PEG SN# 61 SYMMETRY trial 61 CARE HF 61 Matrix Phase 2b 61 Stimuvax R 61 lomitapide 61 AERx iDMS 61 intravenous methylnaltrexone 61 Velcade bortezomib 61 TACI Ig 61 Xcellerated T Cells 61 PRESEPT 61 Thorough QT 61 ganaxolone 61 non nucleoside inhibitor 61 NOX E# 61 AVADO 61 BLA submission 61 rALLy clinical trial 61 CEQ# 61 Phase #b/#a trial 61 Plicera 61 REVIVE Diabetes 61 unblind 61 CUSTOM III 61 ADAGIO study 61 OncoVex 61 IND submission 61 PDE# inhibitors 61 vidofludimus 61 generation purine nucleoside 61 BLA filing 61 LEUKINE 61 Phase #b/#a clinical 61 neratinib 61 Prosaptide 61 BioNumerik 61 RELOVAIR ™ 61 Privigen 61 GetGoal Phase III 61 ANCHOR trial 61 Teriflunomide 61 balsalazide tablet 61 fidaxomicin Phase 3 61 PANVAC VF 61 levodopa induced dyskinesia 61 multicenter Phase III 61 papillary renal cell carcinoma 61 CIMZIA TM 61 Xelox 61 HGS# 61 LymphoStat B TM 61 DEB# 61 Vion Pharmaceuticals 61 GALNS 61 cannabinor 61 CIMZIA ™ 61 Board DSMB 61 Phase Ia 61 IV acetaminophen 61 PROPEL trial 61 Allovectin 7 ® 61 AVERROES 61 PDE4 inhibitor 61 Phase 2a trial 61 StemEx 61 maximally tolerated dose 61 R#/MEM # 61 Phase 2b clinical trials 61 dose proportionality 61 HQK 60 plasma kallikrein inhibitor 60 pain palliation 60 PREOS 60 vivo toxicology 60 blinded randomized 60 PDX pralatrexate 60 omacetaxine mepesuccinate 60 PROMACTA CARES 60 ASSERT trial 60 DCCR 60 Traficet EN 60 modified REGENESIS Phase IIb 60 bicifadine 60 baminercept 60 injectable formulations 60 human IgG1 monoclonal 60 TNFerade TM 60 pharmacodynamic effects 60 GEM OS1 60 oral talactoferrin 60 ThermoDox ® clinical 60 Urocidin 60 elacytarabine 60 ORENCIA ® 60 CLORETAZINE TM VNP#M 60 torezolid phosphate 60 ataluren 60 GSK# [002] 60 LibiGel Phase III 60 number NCT# ClinicalTrials.gov 60 Xanafide 60 Aurexis 60 urocortin 2 60 CLARITY study 60 PhG alpha 1 60 COSTAR II 60 daptomycin 60 Phase 1b clinical trials 60 SinuNase ™ 60 Phase IIb clinical 60 Afatinib 60 Telintra 60 pharmacodynamic markers 60 methylnaltrexone 60 ONGLYZA ™ 60 reduce serum phosphate 60 eliglustat tartrate 60 CIMZIA TM certolizumab pegol 60 ToGA 60 inhaled AAT 60 Sibutramine Cardiovascular Outcomes 60 INSPIRE Trial Phase III 60 gefitinib Iressa 60 oral rivaroxaban 60 intradermal injections 60 Phase #/#a 60 JAK inhibitor 60 Viramidine 60 Urocortin 2 60 ZACTIMA 60 ocrelizumab 60 TREDAPTIVE 60 bardoxolone 60 MIST II 60 alvimopan 60 DXL# 60 COSIRA trial 60 phase 2a 60 PPAR gamma agonist 60 randomized controlled multicenter 60 lumiliximab 60 Tesmilifene 60 intermittent dosing 60 Cinquil 60 Fibrillex TM 60 ORENCIA R 60 Exherin TM 60 Nasulin 60 GAMMAGARD 60 registrational 60 multicenter randomized placebo controlled 60 eprotirome 60 PRADAXA 60 FDA Investigational Device 60 Heplisav 60 corticosteroid dexamethasone 60 thymalfasin 60 CURE AF 60 Phase III Pivotal 60 Poly ICLC 60 ENDEAVOR IV 60 huC# DM4 60 NEO3 60 Elocalcitol 60 oral prodrug 60 IIa trials 60 indiplon capsules 60 Mipomersen 60 Phase IIA 60 histone deacetylase inhibitor 60 Actilon 60 genomic biomarker 60 IMC #B 60 FOLOTYN ® 60 Aflibercept 60 ENDEAVOR III 60 placebo controlled Phase III 60 deforolimus 60 Raptiva R 60 mg/m2 cohort 60 PROMACTA 60 clinicaltrials 60 dacetuzumab 60 HepeX B 60 brivanib 60 novel oral anticoagulant 60 GLYX 60 MAXY alpha 60 placebo controlled clinical 60 Pimavanserin 60 Phase III ADT 60 orBec 60 Hyphanox 60 canakinumab 60 midstage clinical trials 60 vinflunine 60 romidepsin 60 PRECISE trial 60 TASKi2 60 albiglutide 60 oral salmon calcitonin 60 dose escalation clinical 60 AOD# [002] 60 Prestara 60 BAY #-# 60 T Pred 60 LUMINATE 60 Onrigin 60 rEV# 60 PS# DARA 60 pharmacokinetic PK 60 MKC# MKC# PP 60 ENRICH trial 60 APEX PD 60 Vernakalant 60 titration phase 60 IMA# 60 pharmacokinetic pharmacodynamic 60 BENICAR HCT 60 Orathecin 60 MYDICAR 60 ongoing Phase 1b 60 Alvesco R 59 Cloretazine R VNP#M 59 Phenoptin 59 Phase #/#a trial 59 visilizumab 59 PA# [002] 59 lucinactant 59 APTIVUS 59 CCR5 mAb 59 ESBA# 59 designated HVTN 59 eosinophilic asthma 59 granted Ortec 59 ONTAK 59 Vitaxin 59 Ketotransdel 59 ACAPODENE 59 HAART regimens 59 raloxifene Evista 59 multicenter clinical 59 treatment naïve genotype 59 miglustat 59 SAR# [004] 59 midstage studies 59 Phase lll 59 HCD# [002] 59 PFO migraine 59 KNS # 59 Teriparatide 59 HF ACTION 59 CAPHOSOL 59 intranasal formulation 59 SUTENT ® 59 Myocet 59 oral antiviral 59 budesonide MMX Phase III 59 ENGAGE AF TIMI 59 relapsed MCL 59 randomized Phase 2b 59 Xinlay 59 Zevalin consolidation 59 CDP# 59 Panzem 59 desvenlafaxine succinate 59 Targretin capsules 59 OvaRex MAb 59 posaconazole 59 Cethromycin 59 CytoFabTM 59 budesonide MMX 59 vosaroxin 59 Quinamed 59 CA9 SCAN 59 REMINYL ® 59 BeneFIX 59 olanzapine LAI 59 PSN# [002] 59 Octreolin 59 RIGScan CR 59 AZILECT R 59 placebo controlled clinical trials 59 bortezomib Velcade 59 Saforis 59 Phase 1b clinical 59 Cleviprex TM clevidipine 59 prospective multicentre 59 NV1FGF 59 placebo controlled Phase 59 intravenous acetaminophen 59 Tracleer R 59 OncoGel 59 velafermin 59 NSABP C 59 Factor VIIa 59 Degarelix 59 DASISION 59 EchoCRT 59 Solazed 59 rThrombin 59 OPT CHF 59 Arranon 59 Nasdaq ONXX today 59 azilsartan medoxomil 59 Phase III Clinical Trial 59 sNDA submission 59 Avastin adjuvant 59 rBChE 59 PROSTVAC ® 59 NATRECOR R 59 double blinded placebo 59 Fx #A 59 wilate ® 59 nalbuphine ER 59 ENMD # 59 alagebrium 59 lorcaserin Phase 59 IL# PE#QQR 59 prospective multicenter study 59 including eniluracil ADH 59 GTC recombinant human 59 Pivotal Clinical Trial 59 ATL# [001] 59 IIb clinical trial 59 Emezine 59 PROSTVAC TM 59 Oncotype DX colon cancer 59 Triolex 59 EDEMA3 59 SPIRIVA HandiHaler 59 lenalidomide Revlimid R 59 indibulin 59 SEPET TM 59 crizotinib PF # 59 isavuconazole 59 oxypurinol 59 recombinant PSMA vaccine 59 Somatuline R Autogel R 59 Amrubicin 59 ezogabine 59 receptor tyrosine kinase inhibitor 59 lead Aganocide compound 59 verteporfin 59 Catena ® 59 Phase 2b kidney transplant 59 GW# [003] 59 Diamyd ® 59 CRLX# 59 Solorel 59 Pivotal Phase III 59 RhuDex ® 59 iclaprim 59 BrachySil 59 BCIRG 59 pharmacodynamic properties 59 ATIR 59 Vidaza azacitidine 59 Gamunex C 59 rindopepimut 59 samalizumab 59 glatiramer 59 Phase III confirmatory 59 OVATURE 59 eniluracil 59 Actimmune ® 59 BIOV 59 trastuzumab emtansine T DM1 59 clevudine 59 Alferon N 59 Trovax 59 Phase Ib IIa 59 refractory chronic lymphocytic 59 PrevOnco ™ 59 Spiegelmer ® 59 KRN# 59 DU #b 59 Tarvacin TM 59 PROMACTA ® 59 prospective randomized multicenter 59 Aclidinium 59 TRO# 59 Asentar 59 ImmunoVEX HSV2 59 Omigard 59 preclinically 59 ibandronate 59 Bayer HealthCare Onyx Pharmaceuticals 59 teduglutide 59 oral FTY# 59 preclinical pharmacology 59 Allovectin 7 59 Egrifta 59 VA# [002] 59 #I TM# 59 PI3K/Akt pathway inhibitor 59 XOMA 3AB 59 Panzem R NCD 59 PF # [002] 59 MEND CABG II 59 Omacetaxine 59 initiate Phase IIa 59 SILENOR 59 glatiramer acetate 59 biliary tract cancer 59 RE LY ® 59 PRESEPT study 59 Proellex ® 59 CAMMS# 59 Phase 1a 59 Feasibility Trial 59 im peramivir 59 ALK inhibitors 59 hepatitis B vaccine Heplisav 59 Neovasc Reducer 59 severe hypercholesterolemia 59 arzoxifene 59 Kynapid 59 Mylotarg 59 Temsirolimus 59 MADIT II 59 MabThera rituximab 59 lintuzumab SGN 59 solanezumab 59 intravenous iv 58 Perforomist ™ Inhalation Solution 58 Clinicaltrials.gov 58 ganetespib 58 CYT# potent vascular disrupting 58 dose escalation 58 randomized multicenter Phase III 58 faropenem medoxomil 58 CALGB # [002] 58 r hGH 58 SinuNase TM 58 cangrelor 58 lesinurad 58 novel therapeutic antibodies 58 OMP #M# 58 Tocosol Paclitaxel 58 Seliciclib 58 Eniluracil 58 Zybrestat 58 Alfimeprase 58 EndoTAG TM -1 58 Phase IIb 58 controlled multicenter Phase 58 AeroLEF TM 58 pharmacokinetic interactions 58 pharmacokinetics pharmacodynamics 58 Phase III multicenter 58 Zelapar 58 Testosterone MDTS ® 58 optimal dosing 58 sargramostim 58 Q#IR 58 motesanib 58 Revlimid lenalidomide 58 Phase III psoriasis 58 AGILECT R 58 Telavancin 58 Proxinium TM 58 phase Ib clinical 58 BEXXAR 58 hereditary deficiency 58 Neupro R 58 confirmatory Phase IIIb 58 GAP #B# 58 genotypic resistance 58 XmAb# 58 Silodosin 58 Vectibix panitumumab 58 GOUT 58 Keppra XR 58 Indomethacin 58 QLT# 58 CELVAPAN H#N# 58 IMPACT DCM trial 58 Serdolect ® 58 Telik logo TELINTRA 58 vernakalant hydrochloride 58 HGS ETR2 58 #D#C# 58 dosage regimens 58 Cancidas 58 RenalGuard System TM 58 Pivotal Trial 58 Kamada AAT 58 Anidulafungin 58 Febuxostat 58 chemotherapeutic regimen 58 clinical trials 58 EXPAREL ™ 58 Bicifadine 58 OMS#HP 58 HuMax CD# 58 ENESTnd 58 valopicitabine 58 Study #CL# 58 cMET 58 PXD# 58 PREOS R 58 GEM OS2 58 TRIST study 58 pertuzumab 58 initiate Phase 1b 58 dirucotide 58 systemically administered 58 multicenter randomized clinical 58 Augment Injectable 58 plasma pharmacokinetics 58 adalimumab Humira 58 dextofisopam 58 Cethrin 58 investigational HCV polymerase 58 Panzem R 58 Virulizin R 58 ALN VSP Phase 58 aurora kinase 58 DSMB 58 assessing T DM1 58 Cloretazine R 58 Lovaxin C 58 SIMPADICO 58 evaluating mipomersen 58 TPI ASM8 58 HuMax CD4 58 concurrent chemoradiation 58 Dapagliflozin 58 Restanza TM 58 active comparator 58 adecatumumab MT# 58 Ozarelix 58 Hedgehog Pathway Inhibitor 58 pioglitazone HCl 58 PROCHYMAL 58 double blinded randomized 58 pharmacokinetic studies 58 Icatibant 58 HepeX B TM 58 microtubule inhibitor 58 AVN# Phase 58 Phase Ib IIa clinical 58 RIGScan 58 randomized multicentre 58 Removab 58 rt PA 58 AIMM trial 58 PEG PAL 58 investigational protease inhibitor 58 apoptosis inducer 58 histamine dihydrochloride 58 Archexin 58 Canvaxin 58 Phase IIb trial 58 LUX Lung 58 Gabapentin GR 58 ZEGERID Capsules 58 Elvitegravir 58 Phase IIb trials 58 Glybera R 58 CCR5 antagonist 58 CHAMPION PLATFORM 58 Bezielle 58 ARIKACE 58 opioid induced bowel dysfunction 58 evaluating Actimmune 58 evaluating tivozanib 58 Golimumab 58 Interferon beta 1b 58 Veronate 58 trial evaluating PRX# 58 Solulin 58 BYSTOLIC 58 BLP# Liposome Vaccine 58 BST CarGel R 58 ANTEGREN 58 docetaxel Taxotere R 58 HCV NS5B polymerase 58 FavId 58 AQ4N 58 POSIDUR TM 58 Subgroup analysis 58 CBLC# 58 fusion enhancers 58 Sapacitabine 58 alemtuzumab MS 58 integrin inhibitor 58 Oral NKTR 58 Phase III Clinical Trials 58 rFVIIa 58 ZYBRESTAT fosbretabulin 58 Nuvion 58 Preos 58 Onconase 58 DAPT 58 Abbokinase 58 antibiotic telavancin 58 randomized blinded 58 Prodarsan 58 IND Investigational New 58 HCV SPRINT 58 varespladib 58 oral antiplatelet agent 58 trastuzumab DM1 58 esophageal candidiasis 58 Cand5 58 AQUAVAN R 58 antibody MAb 58 MGN# 58 ALVESCO HFA 58 Neuvenge 58 aplindore 58 TRISENOX ® 58 Motesanib 58 pharmacodynamic profile 58 ImmuKnow R 58 ACTILON 58 Urokinase 58 ABSORB trial 58 senicapoc 58 GATTEX ® 58 PRT# 58 immatics 58 lapatinib Tykerb 58 SCENESSE ® 58 lorvotuzumab mertansine 58 CINQUIL 58 Forodesine HCl 58 PD LID 58 Phase 2a 58 Zenpep 58 haematologic 58 LibiGel ® 58 dosing cohorts 58 elagolix 58 EMPHASIS HF 58 noscapine 58 Tekturna HCT 58 Vaxfectin TM 58 Ereska 58 fluvastatin 58 lintuzumab 58 liprotamase 58 follicular Non Hodgkin 58 blinded randomized placebo controlled 58 RE SURGE 58 Trandolapril 58 PARTNER Trial 58 Phase 2b trial 58 octreotide implant 58 Study GL# 58 TMC# [002] 58 Allovectin 7 R 58 Dalbavancin 58 AGHD 58 MEK inhibitor 58 JAK inhibitors 58 ospemifene 58 Onco TCS 58 Lenocta 58 EP #R 58 Tarvacin Anti Viral 58 Silenor NDA 58 Vacc 4x 58 BEZ# 58 AZOR 58 ONTARGET 58 Prodarsan ® 58 sorafenib tablets 58 Fibrillex 58 bazedoxifene 58 RhuDex R 58 chronic thromboembolic pulmonary 58 dalbavancin 58 Ambrisentan 58 Troxatyl 58 obatoclax 58 recurrent herpes labialis 58 bardoxolone methyl 58 LymphoStat B 58 Afinitor everolimus 57 imexon 57 OraTest 57 EXPLORE Xa 57 confirmatory Phase III 57 adecatumumab 57 Annamycin 57 subcutaneous methylnaltrexone 57 interferon gamma 1b 57 Sulonex 57 efficacy endpoint 57 BRILINTA 57 TRISENOX 57 multicenter clinical trials 57 Eltrombopag 57 CLIRS trial 57 HGS ETR1 57 Nexavar sorafenib 57 Phase 2a preventative 57 p# biomarker 57 Kahalalide F 57 edifoligide 57 Alinia 57 Orazol 57 CINTREDEKIN BESUDOTOX 57 Certican 57 LCP AtorFen 57 Diamyd r vaccine 57 viral kinetic 57 hypercholesterolemic patients 57 Urocidin TM 57 Excellagen 57 R# #mg BID 57 rNAPc2 57 VP# [004] 57 LBH# 57 CAELYX 57 K ras mutations 57 weekly subcutaneous injections 57 CAMPATH 57 relapsed MM 57 GRN# 57 HCV polymerase 57 Arzerra TM 57 tropism testing 57 rALLy 57 zileuton CR 57 epoetin alpha 57 E2F Decoy 57 NEBIDO 57 lanthanum carbonate 57 Ixempra 57 sunitinib malate 57 OvaRex 57 XL# SAR# 57 Phase III clinical 57 Capesaris 57 humanised monoclonal antibody 57 IPLEX 57 tafamidis 57 Twinrix 57 CIP TRAMADOL ER 57 peginesatide 57 Phase IIIb 57 Virulizin ® 57 ReN# 57 Loramyc R 57 Elagolix 57 ACOMPLIA R 57 dirucotide MBP# 57 Phase III metastatic melanoma 57 Valtropin 57 Phase 2a clinical 57 Combidex 57 Phase Ib 57 ISTODAX 57 MIRCERA 57 Rasagiline 57 UroVysion 57 Zenvia ™ 57 docetaxel Taxotere ® 57 IMPROVE IT 57 OvaDx 57 MNTX 57 beta 1a 57 Pafuramidine 57 AEG# 57 florbetaben 57 Glybera 57 sipuleucel T 57 daclizumab 57 serum uric acid sUA 57 ponatinib 57 develop HBV reactivation 57 postmarketing surveillance 57 tasocitinib 57 bazedoxifene conjugated estrogens 57 SNS# T 57 dorzolamide 57 aleglitazar 57 Zerenex 57 Surfaxin LS 57 AERx ® 57 OXi# 57 initiated Phase Ib 57 metastatic malignant 57 ularitide 57 ofatumumab HuMax CD# 57 LAS# [002] 57 Tykerb lapatinib 57 confirmatory Phase 3 57 GLIADEL R 57 GVAX ® 57 MGCD# clinical trials 57 ATL/TV# 57 Desmoteplase 57 BNC# 57 Dextofisopam 57 PMA submission 57 telaprevir VX 57 Ophena 57 SYN# 57 Personalized Immunotherapy